Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).
days to go:
Expired
investment:
£311,690
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.
days to go:
Expired
investment:
£388,038
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
